论文部分内容阅读
目的：研究多药耐药相关蛋白在非小细胞肺癌中的表达及其意义。方法：应用单克隆抗体ＱＣＲ－１行ＬＳＡＢ免疫组化法研究６１例非小细胞肺癌组织的多药耐药相关蛋白表达水平。结果：肺癌组织中多药耐药相关蛋白表达总阳性率为６８．９２％；癌旁正常肺组织呈阴性或弱阳性表达；高和中分化肺癌多药耐药相关蛋白表达的阳性率高于低分化癌（Ｐ＜０．００５）；Ⅰ～Ⅱ期肺癌多药耐药相关蛋白表达的阳性率高于Ⅲ～Ⅳ期者（Ｐ＜０．０１）。结论：多药耐药相关蛋白是非小细胞肺癌多药耐药的重要参与因素，其表达与非小细胞肺癌分化程度及临床分期相关。
Objective: To study the expression and significance of multidrug resistance-associated protein in non-small cell lung cancer. Methods: The expression of multidrug resistance-associated protein in 61 non-small cell lung cancer tissues was studied by immunohistochemistry using monoclonal antibody QCR-1 and LSAB. Results: The total positive rate of multidrug resistance-associated protein expression in lung cancer tissue was 68.92%; the normal lung tissue was negative or weakly positive in lung cancer tissues; the positive rate of multidrug resistance-associated protein expression in high and moderately differentiated lung cancer was higher The positive rate of multidrug resistance-associated protein expression in poorly differentiated cancer (P<0.005), stage I-II lung cancer was higher than that in stage III-IV (P<0.01). CONCLUSION: Multidrug resistance-associated protein is an important factor for multidrug resistance in non-small cell lung cancer, and its expression is related to the differentiation and clinical stage of NSCLC.